Cannabis and schizophrenia: results of a follow-up study
Cannabis and schizophrenia: results of a follow-up study
复制标题
DOI：
10.1007/s004060050064
复制
发表时间：
1999-02-01
影响因子：
4.7
通讯作者：
Caspari, D
中科院分区：
文献类型：
--
作者：
Caspari, D
共有 39 名在入院时有大麻滥用史的精神分裂症患者与年龄、性别和入院年份相匹配的无药物滥用的对照组精神分裂症患者进行了比较。在 68.7 +/- 28.3 个月后的随访中，可以对 27/39 例病例和 26/39 例对照进行调查。 8/27 例（30%）继续吸食大麻，6/27 例（22%）成为酗酒者。对照组中只有一名患者开始酗酒。既往吸食过大麻的患者再住院次数明显增多，心理社会功能往往更差，并且在精神病理综合征“思维障碍”（BPRS）和“敌意”（AMDP）方面得分显着更高。这些结果证实了大麻滥用对精神分裂症患者长期结果的重大影响。
A total of 39 schizophrenic patients with a history of current cannabis abuse at index admission was compared with a control group of schizophrenics without substance abuse matched for age, gender, and year of admission. At follow-up after 68.7 +/- 28.3 months, 27/39 cases and 26/39 controls could be investigated. 8/27 cases (30%) had continued cannabis abuse, 6/27 (22%) had become alcohol abusers. Only one patient of the control group had started abusing alcohol. Patients with previous cannabis abuse had significantly more rehospitalizations, tended to worse psychosocial functioning, and scored significantly higher on the psychopathological syndromes "thought disturbance" (BPRS) and "hostility" (AMDP). These results confirm the major impact of cannabis abuse on the long-term outcome of schizophrenic patients.